Figure 8
The protein levels of pSTAT3 and pVEGFR2 in HepG2 cancer treated cells. The protein levels were as follows: (A) protein levels of pSTAT3 upon separate and combined treatments with sorafenib, bevacizumab, panitumumab and ramucirumab; (B) protein level of pVEGFR2 upon separate and combined treatments with sorafenib and ramucirumab. Each value represents the mean ± SD (n = 3). *P < 0.05 compared to untreated HepG2 cancer cells (control). #P < 0.05, compared to sorafenib treated HepG2 cancer cells.
